Imperial College London-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Imperial College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013594
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Imperial College London (Imperial) is a research university that offers educational services. The university provides undergraduate and postgraduate courses. It offers courses in the field of science and technology, agriculture, business, the humanities, and medicine. It conducts clinical trials in the therapeutic areas of cancer, cardiovascular and diabetes, emergency and critical care, HIV and infectious disease, surgery and robotics, and others. Imperial’s customized programs include finance, management, innovation and marketing, among others. The university offers collaborative research to promote connections between interests and research expertise. It also designs and conducts medical device trials. Imperial is headquartered in London, the UK.

Imperial College London – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Imperial College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Imperial College London, Medical Devices Deals, 2011 to YTD 2017 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Imperial College London, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Natera Enters into Agreement with Imperial College London and University of Leicester 12
Smith & Nephew Enters into Agreement with Imperial College London 13
Optibrium Enters into Partnership with Imperial College London and DNDi 14
Domainex Expands its Agreement with Imperial College London 15
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 16
Prosonix Enters Into Research Agreement With Imperial College London 17
UCB Enters Into Co-Development Agreement With Imperial College London 18
Medical Research Council, Imperial College, King’s College and UCL Form Joint Venture 19
ValiRx Enters Into Co-Development Agreement With Imperial College London 20
Imperial College London, King’s College London, University College London, Medical Research Council And GSK Form Joint Venture 21
Imperial College London – Key Competitors 23
Imperial College London – Key Employees 24
Imperial College London – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Strategy And Business Planning 26
Apr 06, 2016: UK’s First Commercial Synthetic Biology Foundry Goes Into Production 26
Government and Public Interest 27
Nov 15, 2017: Signalling protein found to drive heart scarring and organ failure 27
Oct 31, 2017: Revisiting abandoned treatments in fight against antimicrobial-resistant gonorrhea 28
Sep 25, 2017: Human antibodies from dengue patients can effectively treat Zika infection in mice 29
Sep 25, 2017: Antibody protects against both Zika and dengue, mouse study shows 31
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 33
May 12, 2017: A lead candidate for immunotherapy may increase tumour growth in certain cancers 34
Mar 17, 2017: Molecular therapy set to protect at-risk patients against heart attack and stroke 36
Oct 10, 2016: New study to tackle ADHD in young prisoners 37
Sep 22, 2016: Trust receives £90 million award for biomedical research 39
Sep 19, 2016: Parkinson’s disease protein plays vital ‘marshalling’ role in healthy brains 40
Sep 09, 2016: Activity of Huntington’s disease gene curbed for six months in mice 41
Jul 25, 2016: Flu vaccine may reduce risk of death for type 2 diabetes patients 43
May 17, 2016: Psilocybin for treatment-resistant depression 44
Mar 16, 2016: Antibiotic resistance ‘high among children with urinary tract infections’ 46
Mar 15, 2016: High antibiotic resistance levels in children could leave some treatments ineffective 47
Jan 06, 2016: Flu virus hijacking tactics revealed by scientists, paving way for new treatments 48
Product News 49
Oct 13, 2016: Shanghai Medicilon: Researchers Create A Gene Therapy Treatment That May Prevent Alzheimer Disease 49
Sep 27, 2016: Blood pressure drug may boost effectiveness of lung cancer treatment 51
Jul 28, 2016: Two New Scientific Studies Confirm Benefits of Orafti Synergy1 in Reducing the Risk of Diabetes 52
Other Significant Developments 53
Nov 08, 2017: NPL and Imperial College London Launch a New Virtual Lab to Establish the UK Centre for Engineering Biology, Metrology and Standards 53
Nov 29, 2016: Global research network hunts the missing link between genetics and environmental factors to unlock the secrets of global diseases such as cancer and diabetes to revolutionise healthcare 54
Feb 02, 2016: Heptares Launches “Orbit” Initiative – A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS) 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Imperial College London, Pharmaceuticals & Healthcare, Key Facts 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Imperial College London, Deals By Therapy Area, 2011 to YTD 2017 9
Imperial College London, Medical Devices Deals, 2011 to YTD 2017 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Natera Enters into Agreement with Imperial College London and University of Leicester 12
Smith & Nephew Enters into Agreement with Imperial College London 13
Optibrium Enters into Partnership with Imperial College London and DNDi 14
Domainex Expands its Agreement with Imperial College London 15
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 16
Prosonix Enters Into Research Agreement With Imperial College London 17
UCB Enters Into Co-Development Agreement With Imperial College London 18
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 19
ValiRx Enters Into Co-Development Agreement With Imperial College London 20
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 21
Imperial College London, Key Competitors 23
Imperial College London, Key Employees 24
Imperial College London, Subsidiaries 25
Imperial College London, Joint Venture 25

★海外企業調査レポート[Imperial College London-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Romelectro S.A.:企業の戦略的SWOT分析
    Romelectro S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Strongbridge Biopharma plc (SBBP)-製薬・医療分野:企業M&A・提携分析
    Summary Strongbridge Biopharma plc (Strongbridge), formerly Cortendo plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokale …
  • Erasmus MC-医療機器分野:企業M&A・提携分析
    Summary Erasmus MC (Erasmus) is a medical institute that offers patient care, research and educational services. The institute offers graduate and doctoral programs in health sciences, biomedical sciences, molecular medicine and cardiovascular sciences. It conducts research in the areas of biochemis …
  • Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報
    Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that …
  • Ziehm Imaging GmbH-医療機器分野:企業M&A・提携分析
    Summary Ziehm Imaging GmbH (Ziehm Imaging) is a medical device company that specializes in the development, production and global marketing of mobile X-ray based imaging solutions. The company's product portfolio includes ziehm vision RFD 3D, ziehm vision RFD hybrid edition, ziehm vision RFD, ziehm …
  • Valeant Canada LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical products manufacturing company. The company offers products such as aczone, airomir, aldara, benzaclin topical gel, benzamycin, biacna topical gel, C.E.S. tablets, carbolith, ca …
  • Chugach Electric Association, Inc.:企業の発電所・SWOT分析2018
    Chugach Electric Association, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information o …
  • Cimarex Energy Co (XEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Cimarex Energy Co (Cimarax) is an independent upstream oil and natural gas company. It carries out the exploration and production of crude oil, natural gas and natural gas liquids (NGLs). The company’s operations are concentrated in two main areas namely the Mid-Continent region consisting o …
  • Polyplex (Thailand) Public Company Limited:企業の戦略・SWOT・財務情報
    Polyplex (Thailand) Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Polyplex (Thailand) Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Steel Authority of India Ltd:企業のM&A・事業提携・投資動向
    Steel Authority of India Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Steel Authority of India Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Nottingham Building Society:企業の戦略・SWOT・財務情報
    Nottingham Building Society - Strategy, SWOT and Corporate Finance Report Summary Nottingham Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Endava Limited:企業の戦略・SWOT・財務分析
    Endava Limited - Strategy, SWOT and Corporate Finance Report Summary Endava Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ChanTest Corp-製薬・医療分野:企業M&A・提携分析
    Summary ChanTest Corp (ChanTest), a subsidiary of Charles River Laboratories International Inc is a contract research organization that discovers and develops drugs in ion channel and GPCR biology fields. The organization's ion channel products include cell lines and antibodies. Its other products c …
  • Gunvor Group Limited-石油・ガス分野:企業M&A・提携分析
    Summary Gunvor Group Limited (Gunvor) is a vertically integrated energy trading company. It is one of the global traders of physical crude oil; refined products and energy; and metals and bulk materials. The company provides integrated trading products and logistics service to connect suppliers upst …
  • Immofinanz AG:企業のM&A・事業提携・投資動向
    Immofinanz AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Immofinanz AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Bank Hapoalim Bm:企業の戦略・SWOT・財務分析
    Bank Hapoalim Bm - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim Bm - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Crrc Corporation Limited
    Crrc Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Crrc Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Pilot Energy Ltd (PGY):電力:M&Aディール及び事業提携情報
    Summary Pilot Energy Ltd (Pilot), formerly Rampart Energy Ltd is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-507-P, Australia WA-503-P and Aus …
  • Erytech Pharma SA (ERYP):製薬・医療:M&Aディール及び事業提携情報
    Summary Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are …
  • Congenica Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers clinical decision support software and services. The company provides research and experimental development on biotechnology. Its technology SAPIENTIA is used to personalize patient care through accurate diagnoses, drug develop …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆